(NASDAQ: PYXS) Pyxis Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Pyxis Oncology's earnings in 2026 is -$88,727,000.On average, 11 Wall Street analysts forecast PYXS's earnings for 2026 to be -$107,004,187, with the lowest PYXS earnings forecast at -$121,792,435, and the highest PYXS earnings forecast at -$94,584,729. On average, 11 Wall Street analysts forecast PYXS's earnings for 2027 to be -$99,163,831, with the lowest PYXS earnings forecast at -$138,957,811, and the highest PYXS earnings forecast at -$63,932,270.
In 2028, PYXS is forecast to generate -$95,852,531 in earnings, with the lowest earnings forecast at -$148,766,598 and the highest earnings forecast at -$30,652,458.